My friend Alex Reid just might have created my favorite strategy right now. You see, Alex has figured out how to cut-the-corner so to speak, and be one of the laziest traders possible…. While still showing his traders how to target big money. This past year, his LIVE “lazy trade” alerts have delivered impressive results—and that’s only a fraction of the opportunities he’s shared. And that’s just just a quarter of the total trade alerts he’s sent out. The true total profit potential his beta-testers have had the chance to target is far larger than $20k.

Alex recorded a special video training where he reveals exactly how much.

Rafael Amado Biography and Net Worth

CMO of Allogene Therapeutics

Rafael G. Amado, MD, is the Executive Vice President of Research and Development and Chief Medical Officer of Allogene. Rafael has over 15 years of biotechnology and pharmaceutical industry experience leading clinical and research teams. He most recently served as President of R&D, after serving as Chief Medical Officer, at Adaptimmune. Previously, he held several roles of increasing responsibility at GSK, most recently as Senior Vice President and Head of Oncology R&D. Prior to GSK, Rafael served as Executive Director of Therapeutic Oncology at Amgen, where he was responsible for worldwide clinical research strategy and execution and oversaw development activities for several investigational agents for molecularly characterized tumors. Before joining Amgen, he was on the faculty at the University of California, Los Angeles, most recently serving as Assistant Clinical Professor, Department of Medicine, Division of Hematology/Oncology. Rafael received an MD from the University of Seville School of Medicine and completed his internship and residency in internal medicine at Michael Reese Hospital and Medical Center, a University of Chicago-affiliated hospital. He completed a fellowship in hematology/oncology at the University of California, Los Angeles.

What is Rafael Amado's net worth?: The estimated net worth of Rafael Amado is at least $41,592.51 as of March 15th, 2024. Dr. Amado owns 20,093 shares of Allogene Therapeutics stock worth more than $41,593 as of December 26th. This net worth approximation does not reflect any other investments that Dr. Amado may own. Learn More about Rafael Amado's net worth.
How do I contact Rafael Amado?: The corporate mailing address for Dr. Amado and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on Rafael Amado's contact information.
Has Rafael Amado been buying or selling shares of Allogene Therapeutics?: Rafael Amado has not been actively trading shares of Allogene Therapeutics in the last ninety days. Most recently, Rafael Amado sold 2,000 shares of the business's stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $11.97, for a transaction totalling $23,940.00. Following the completion of the sale, the chief marketing officer now directly owns 540,257 shares of the company's stock, valued at $6,466,876.29. Learn More on Rafael Amado's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), and Owen Witte (Director). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, Allogene Therapeutics insiders bought shares 2 times. They purchased a total of 1,724,327 shares worth more than $5,000,681.30. During the last year, insiders at the sold shares 3 times. They sold a total of 29,557 shares worth more than $66,041.84. The most recent insider tranaction occured on December, 9th when Director Deborah M Messemer sold 9,136 shares worth more than $19,916.48. Insiders at Allogene Therapeutics own 24.3% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 12/9/2024.

Rafael Amado Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2022	Sell	2,000	$11.97	$23,940.00	540,257
7/5/2022	Sell	2,000	$11.44	$22,880.00	542,257
6/21/2022	Sell	2,000	$11.18	$22,360.00	544,257
5/19/2022	Sell	11,500	$7.40	$85,100.00	546,257
3/15/2022	Sell	5,169	$7.71	$39,852.99
10/1/2021	Sell	11,507	$24.35	$280,195.45
10/7/2020	Sell	16,538	$39.40	$651,597.20	111,677

Rafael Amado Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $2.07

$2.02

$2.07

50 Day Range

MA: $2.44

$1.84

$3.22

2 Week Range

Now: $2.07

$1.78

$5.78

Volume

146,789 shs

Average Volume

2,477,646 shs

Market Capitalization

$434.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.83

$20k in extra income?

From DTI | Ad